Nina Paleologos to Prognosis
This is a "connection" page, showing publications Nina Paleologos has written about Prognosis.
Connection Strength
0.078
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-192.
Score: 0.020
-
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
Score: 0.018
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8.
Score: 0.015
-
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar; 92(1):57-63.
Score: 0.012
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34.
Score: 0.008
-
Salvage chemotherapy for oligodendroglioma. J Neurosurg. 1996 Oct; 85(4):597-601.
Score: 0.005